Well Done LLC Purchases 42 Shares of Danaher Co. (NYSE:DHR)

Well Done LLC grew its position in Danaher Co. (NYSE:DHR) by 1.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,551 shares of the conglomerate’s stock after acquiring an additional 42 shares during the period. Well Done LLC’s holdings in Danaher were worth $987,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Howard Capital Management Group LLC increased its holdings in shares of Danaher by 4.1% during the 3rd quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 48 shares during the last quarter. Onyx Bridge Wealth Group LLC bought a new position in Danaher during the third quarter worth $207,000. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Danaher by 1.0% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 78,290 shares of the conglomerate’s stock valued at $21,766,000 after purchasing an additional 778 shares during the last quarter. Ellsworth Advisors LLC bought a new position in shares of Danaher in the third quarter valued at about $223,000. Finally, Compass Wealth Management LLC lifted its stake in shares of Danaher by 6.5% during the 3rd quarter. Compass Wealth Management LLC now owns 25,973 shares of the conglomerate’s stock worth $7,221,000 after buying an additional 1,585 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Wells Fargo & Company began coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Barclays lifted their price target on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Stephens started coverage on Danaher in a research report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 price objective for the company. Finally, Leerink Partners boosted their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Trading Up 0.2 %

NYSE DHR traded up $0.41 on Friday, reaching $272.39. The company had a trading volume of 243,951 shares, compared to its average volume of 2,709,507. The firm has a market cap of $201.76 billion, a price-to-earnings ratio of 46.10, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The business has a 50 day moving average of $270.60 and a two-hundred day moving average of $259.73.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the company posted $2.05 EPS. The business’s revenue was down 2.9% on a year-over-year basis. Analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.